Osilodrostat
Payments companies reported to CMS as associated with Osilodrostat. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Osilodrostat, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Osilodrostat
These are the largest totals companies reported as associated with Osilodrostat. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Maria Fleseriu | Portland, OR | Endocrinology, Diabetes & Metabolism | $26,977.35 |
| Beverly Biller | Boston, MA | Endocrinology, Diabetes & Metabolism | $18,761.78 |
| Richard Auchus | Ann Arbor, MI | Endocrinology, Diabetes & Metabolism | $12,164.79 |
| Irina Bancos | Rochester, MN | Endocrinology, Diabetes & Metabolism | $11,674.58 |
| Muthiah Vaduganathan | Boston, MA | Cardiovascular Disease | $10,754.40 |
| John Buse | Chapel Hill, NC | Endocrinology, Diabetes & Metabolism | $9,136.37 |
| Anthony Heaney | Los Angeles, CA | Endocrinology, Diabetes & Metabolism | $8,568.31 |
| Stephen Greene | Durham, NC | Advanced Heart Failure and Transplant Cardiology | $8,490.98 |
| Javed Butler | Jackson, MS | Advanced Heart Failure and Transplant Cardiology | $8,320.96 |
| Eliza Geer | New York, NY | Endocrinology, Diabetes & Metabolism | $6,699.00 |
Prescribed Osilodrostat?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.